3.885USD-0.13%Mkt Cap: 299.87M USDP/E: —Last update: 2026-05-26
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and preve…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap299.87M USD
Enterprise Value189.73M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.62M USD
Revenue/Share—
Last Price3.885 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCA2849025093
Valuation
P/E (Trailing)—
P/E (Forward)-5.38
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.94
EPS (TTM)-0.77
EPS (Forward)-0.72
52W Range
1.35078% of range4.600
52W High4.600 USD
52W Low1.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-56.26%
ROA-26.99%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-62.34M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-13.23%
Net Debt-110.53M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio8.44
Quick Ratio8.30
Book Value/Sh1.322 USD
Cash/Share1.439 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 5, 2020
Splits
Last Split1:18
Split DateOct 5, 2020
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)8.200 USD
Target Range5.000 USD – 12.00 USD
# Analysts5
Ownership
Shares Out.77.19M
Float64.94M
Insiders1.09%
Institutions59.23%
Short Interest
Short Ratio4.5d
Short % Float9.79%
Short % Out.9.79%
Shares Short7.55M
Short (prev mo.)7.19M
Technical
SMA 503.386 (+14.7%)
SMA 2002.632 (+47.6%)
Beta0.95
S&P 52W Chg28.31%
Avg Vol (30d)1.53M
Avg Vol (10d)1.16M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—